News and Trends 29 Nov 2016 One Step Closer to the First Triple Combination Therapy for Cystic Fibrosis Galapagos and AbbVie are closer to launching a cystic fibrosis treatment that can outperform the current standards. However, gene therapy and CRISPR might end up taking over in the long term. Despite being abandoned by AbbVie in its rheumatoid arthritis program, Galapagos and the big US pharma expanded their cystic fibrosis partnership in May. The […] November 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Nov 2016 New British Partnership set to Cure Rare Diseases with Gene Therapy Oxford BioMedica and Orchard Therapeutics are partnering up to bring gene therapy to the market and treat rare diseases for which no cure is available yet. Oxford BioMedica develops lentiviral vectors for gene and cell therapy applications. The company just announced a partnership with another biotech from the UK’s golden triangle, Orchard Therapeutics. The deal is […] November 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2016 Finally a Cure for the Common Cold? And it’s Needle-free! Mucosis is starting Phase I trials for SynGEM, a needle-free vaccine against RSV, which causes 200k deaths per year and has a huge cost for both healthcare and the economy. Mucosis is a biotech from the Netherlands developing needle-free vaccines. The company has now initiated the first human trial for SynGEM, a nasal spray vaccine against […] November 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 28 Nov 2016 Needle-Free Diabetes Monitoring: Interview with the Co-Founder of GlucoWise The needle-free revolution for diabetes is coming! We interviewed Panos Kosmas, co-founder of MediWise, to get the juicy details of GlucoWise. This revolutionary wireless device could free the more than 422 million people living with diabetes worldwide from the daily pain of conventional glucose monitoring. Panos Kosmas is the co-founder and Chief Technical Officer of MediWise, a […] November 28, 2016 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Nov 2016 Fruit Flies are the Artists behind these Astounding Exhibitions The Fly Printer by Laura Beloff transforms fruit flies into artists behind pieces that highlight the limits of always making humans the point of reference in technology. Fruit flies are a very common model organism for experimentation in biotech. Now, a piece of art at the Open Fields exhibition in Riga is inverting the roles […] November 26, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 25 Nov 2016 Structural Biology meets Drug Discovery in this Cool Company After an amazing day in Paris for Labiotech Refresh, we head back to Germany to meet Proteros. The company is working non-stop to provide drug candidates against some of the hottest targets in biotech. City: Munich, Germany Founded: 1999 Employees: 80+ Financial data: The company just announced a €157M ($167M) deal with MSD Mission: Proteros’ expertise in structural biology […] November 25, 2016 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2016 Fighting for the next Asthma Blockbuster: Italy gets in the way of Novartis Chiesi has bought Atopix Therapeutics and stepped into the fight for the next asthma blockbuster. Can it take on Novartis in the competition for what is expected to grow to a €24B market in 2024? Chiesi is an Italian pharma with a strong focus on respiratory diseases. To strengthen its pipeline, the company has acquired the […] November 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2016 Sanofi quietly leaves Bladder Cancer Patients in the lurch Sanofi is halting the production of the main bladder cancer drug. In response, doctors are pressuring regulatory agencies to take action against this instance of a widespread issue of drug shortages. Sanofi Pasteur announced last week that it will be shutting down the production of the cancer drug BCG (TheraCys and ImmuCyst) in mid-2017. This drug […] November 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2016 One Antibody to Neutralize 98% of All HIV Strains: Closer to a Cure? A new hope for HIV: a single antibody that can target nearly all viral strains at once. What does it mean for the search of a global cure? Last week, a research article in Cell Immunity reported a detailed study of an antibody that could neutralize 98% of HIV strains. The N6 antibody can also […] November 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2016 Celyad’s Autologous CAR-T Therapy enters Phase Ib Celyad has received approval to start Phase Ib trials in Belgium with its autologous CAR-T therapy, which can target 80% of tumors. After a successful Phase I in leukemia and myeloma, Celyad is ready to start a Phase Ib trial for its autologous NKR-2 in 7 cancer indications, now including solid tumors. The new trial, aimed to examine different […] November 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Nov 2016 Teaching Bacteria to make Living, Evolving Typography Ori Elisar is an Israeli artist working on Biodesign. His globally-acclaimed project uses bacteria to create living typography that changes over time to represent the evolution of the Hebrew language. The Living Language project uses Paenibacillus vortex bacteria to create living typography. To represent the evolution of the Hebrew language, the artist makes bacteria grow […] November 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2016 These Spider Silk Sneakers from Adidas Are Biodegradable Adidas just unveiled a biodegradable sneaker prototype made with a spider silk biomaterial manufactured by the German biotech AMSilk. Is this the beginning of a new era for sustainable biomaterials? AMSilk, located near Munich, is the world’s first biotech supplying synthetic silk biopolymers for textiles, cosmetics and medical devices. The company’s 100% biodegradable and vegan […] November 18, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email